Etirinotecan pegol: Phase II started

Nektar said investigators at Stanford Cancer Institute began an open-label, U.S. Phase II trial to evaluate NKTR-102 every 3 weeks in about 20 patients with bevacizumab-resistant high-grade glioma. G...